|
Nov 7
|
Xencor Sells Portion of Royalties and Milestones from Ultomiris® and Monjuvi® to OMERS Life Sciences for $215 Million
|
|
Nov 3
|
Xencor Presents Preclinical Data from Multiple XmAb® Research Programs at the SITC Annual Meeting
|
|
Aug 8
|
Analysts Just Published A Bright New Outlook For Xencor, Inc.'s (NASDAQ:XNCR)
|
|
Aug 7
|
Xencor, Inc. (NASDAQ:XNCR) Q2 2023 Earnings Call Transcript
|